Impfungen in der Entwicklung
Folgende Impfungen werden zur Zeit entwickelt:
Impfung |
Produktname |
Hersteller |
Anmerkungen |
| Adenovirus Impfung | |||
| Alzheimer Impfung | |||
| Bartonellose Impfung | |||
| Borrelia miyamotoi Impfung | |||
| Burkholderia mallei Impfung | |||
| Krebs Impfungen | (Jonhson, K. (March 21, 2013). "Prostate Cancer Vaccine Shows Promise". Medscape Today. Retrieved April 24, 2013; McFadden, M. (October 11, 2012). "Revolutionary breast cancer vaccine 100% effective in mice: awaits human trials". WNDU. Retrieved May 12, 2013.) | ||
| Karies Impfung | (Shivakumar, K. M.; Vidya, S. K.; Chandu, G. N. (2009). "Dental caries vaccine". Indian journal of dental research : official publication of Indian Society for Dental Research 20 (1): 99–106. ) | ||
| Chagas Krankheit Impfung | |||
| Coccidioidomykose Impfung | (Cox, R. A.; Magee, D. M. (2004). "Coccidioidomycosis: Host Response and Vaccine Development". Clinical Microbiology Reviews 17 (4): 804–839, table 839 contents. ) | ||
| Coxsackie A Virus Impfung | |||
| Coxsackie B Virus Impfung | (Kim, D. S.; Nam, J. H. (2010). "Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines". Expert Opinion on Biological Therapy 10 (2):) | ||
| Cytomegalovirus Impfung | GlaxoSmithKline | (Schleiss, M. R. (2008). "Cytomegalovirus vaccine development". Current topics in microbiology and immunology. Current Topics in Microbiology and Immunology 325: 361–382. ) | |
| Ebola Impfung |
Crucel GenPh |
(Erickson, D. (January 21, 2013). "Hamilton researchers help make breakthrough on Ebola vaccine". Billings Gazette. Retrieved May 29, 2013.) | |
| Epstein–Barr Virus Impfung | (Pullen, L.C. (November 7, 2011). "Epstein-Barr Virus Vaccine May Soon Enter Phase 3 Trial". Medscape Today. Retrieved April 24, 2013.) | ||
| Ehrlichiose Impfung | (Rudoler, N.; Baneth, G.; Eyal, O.; Van Straten, M.; Harrus, S. (2012). "Evaluation of an attenuated strain of Ehrlichia canis as a vaccine for canine monocytic ehrlichiosis". Vaccine 31 (1): 226–233.) | ||
| Hepatitis C Impfung |
Chronvac-C®
|
Inovio Pharmaceuticals
Blue Bell, PA
ChronTech Pharma
Huddinge, Sweden
Okairos
|
("Hepatitis C vaccine by Inovio could be tested in humans by end of year". Philadelphia Business Journal. January 9, 2013. Retrieved April 24, 2013.) |
| HIV Impfung |
DermaVir™
Patch
HIVAX™
MVA-BN®
|
Genetic Immunity Crucell GlaxoSmithKline GeoVax Novartis |
|
| H7N9 Impfung | |||
| Lepra Impfung | |||
| Borreliose Impfung | ("Lyme Disease Vaccine". Lyme Info. Retrieved April 24, 2013.) | ||
| Malaria Impfung |
Crucell GlaxoSmithKline |
||
| Molluscum contagiosum Impfung | |||
| Marburg virus Impfung | |||
| Human Metapneumovirus (hMPV) Impfung | |||
| Middle East Respiratory Syndrom (MERS) Impfung, | |||
| Norovirus Impfung | (Sifferlin, A. (March 22, 2013). "Norovirus leading cause of intestinal disorders in kids". CNN. Retrieved April 24, 2013.) | ||
| Staphylococcus aureus Impfung | |||
| Treponema pallidum Impfung | |||
| Dengue Fieber Impfung |
DENVax™
|
GlaxoSmithKline SanofiPasteur Inviragen |
|
| RSV (Respiratory syncytial virus) Impfung | |||
| Severe acute respiratory syndrome (SARS) Impfung | |||
| Scharlach Impfung | |||
| Streptococcus pyogenes Impfung | |||
| Staphylococcus aureus | Pfizer | ||
| SV40 Simian vacuolating virus 40 Antikrebs Impfung | SV-40 Virus befand sich als "Verunreinigung" in Millionen von Polioimpfungen in den 50/60er Jahren | ||
| West Nile virus Impfung | |||
| Yersinia pestis Impfung | DynPort Vaccin |
Stand 2006
Zur Zeit (2006) befinden sich mehrere Impfungen in der Entwicklung. Einige Impfungen stehen kurz vor der Marktreife, bei anderen Impfungen wird es noch Jahre dauern.
| Produktname | Hersteller | Impfung gegen | Entwicklungsstadium |
| Clamydia trachomatis Impfung | Emergent Bio Solutions | Clamydia trachomatis | vorklinisch |
| Cervarix | GlaxoSmithKline | Papillomavirus | Phase 3, jugendliche Mädchen |
| Cholera Guard | Avant immunotherapeutics | Cholera | Phase 2b |
| CAIV-T | Medimmune | Influenza | Phase 3 |
| Influenza | Merck | Influenza | Phase 1 |
| Flu-Intradermal | Sanofi Pasteur | Influenza | Phase 2b |
| FluNsure | GlaxoSmithKline | Influenza | Phase 2, Kinder |
| Haemophilus Influenza Impfung | Emergent Bio Solutions | Mittelohrentzündung | Phase 1 |
| HIV Impfung | Merck | HIV | Phase 2 |
| HPV Impfung | Merck | HPV | Phase 2 |
| Group A strep Impfung | Wyeth | Streptokokken | vorklinisch |
| GBS Impfung | Emergent Bio Solutions | GBS | Phase 1 |
| Meningitis B Impfung | GlaxoSmithKline | Meningitis B | Phase 2 |
| Meningitis B Impfung | Wyeth | Meningitis B | Phase 1 |
| Neisseria meningititis A/ C Impfung | GlaxoSmithKline | Meningitis A und C | Phase 2-3 |
| Numax | Medimmune | Infektionen des unteren Atemtraktes | Phase 3 |
| 13-valenter Pneumokokkenimpfstoff | Wyeth | Pneumokokken | Phase 3 |
| Pentacel | Sanofi Pasteur | Hib, DTaP, Polio | angemeldet |
| RSV-Impfung | Wyeth | RSV-Virus | vorklinisch |
| Salmonellen Impfung | Avant Immunotherapeutics | Salmonella typhii | Phase 1 |
| Simplirix | GlaxoSmithKline | Herpes genitalis | Phase 3 |
| 26-valenter Streptokokken Impfstoff | GlaxoSmithKline | Streptokokken der Gruppe A | Phase 1/2 |
| Streptokokkus pneumoniae | Medimmune | Pneumokokken Erkrankungen | Phase 1 |
| Streptorix | GlaxoSmithKline | Streptokokkus pneumoniae | Phase 3 |
